Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Better, Faster, Smaller: Personalized Medicine Could Bring R&D Savings

Executive Summary

PHILADELPHIA - One near-term benefit of adopting a personalized medicine approach to drug development would be a lower cost for clinical trials by conducting smaller, faster studies that will produce better results and help companies make go/ no go decisions sooner, according to speakers at the Wharton Health Care Business Conference

You may also be interested in...



Xalkori And Zelboraf: The Highs And Lows Of Commercializing Targeted Cancer Drugs

Pfizer’s lung cancer drug Xalkori and Roche’s melanoma drug Zelboraf launched last year in tandem with companion diagnostics. But a slow launch trajectory compared to other recent cancer drugs points to pitfalls for marketing a drug to just a subset of patients.

Critical Path Consortium To Allow Patents But Preserve Access For Partners

The Predictive Safety Testing Consortium will allow companies to patent safety testing methodologies developed through the collaboration, but firms will be required to grant access to other members

Targeted Oncologic Therapies Demand New Approach to Phase II/III Trials

Targeted cancer therapies should be studied in large Phase II programs that incorporate biomarkers, a panelist said at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla

UsernamePublicRestriction

Register

PS049351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel